Here's a little item from nytimes.com (3/12/06) that slipped by me -- but my friend Ann Banks flagged it:
"Last year, Genentech raised the price of Tarceva, a lung-cancer drug, by about 30 percent, to $32,000 for a year's treatment. In an interview last month, Dr. Susan Desmond-Hellmann, the president of product development for Genentech, said that the company had raised Tarceva's price because the drug works better than Genentech had anticipated. 'Tarceva was a more powerful and more active agent than what we understood at the time of launch, and so more valuable,' she said."
I can't do better than quote Ann on this one:
So "I guess the lower-priced drugs are the ones that don't work?"
Just think about that one...